Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment

Inclusion Criteria: All subjects * Able to provide written informed consent to participate in this study after reading the ICF * Subjects is able to understand and willing to cooperate and comply with the Protocol restrictions and requirements. * A body weight of ≥45 kg in males or ≥40 kg in females and a body mass index ranging from 18 to 30 kg/m2 Hepatic impaired subjects (in addition) * A Child-Pugh score of 5 or 6 for subjects with mild hepatic impairment, and between 7 and 9, inclusive, for subjects with moderate hepatic impairment * Chronic and stable hepatic impairment Healthy subjects (in addition) * Subject with normal hepatic function * Good health and free from clinically significant illness or disease Exclusion Criteria: All subjects * Presence or history of severe allergy to food, or any medicinal product or relevant excipient that is of clinical significance * Subjects were previously administered MCI-186. * Positive urine drug screen (if not due to concomitant medication) or alcohol test * History of drug abuse * Presence of alcohol abuse * Presence of active infection requiring antibiotics * Positive test for human immunodeficiency virus (HIV) antigen/antibody * Uncontrolled, or untreated hypertension defined as systolic blood pressure (SBP)\>160 mmHg and/or diastolic blood pressure (DBP)\>100 mmHg * eGFR \<60 mL/min/1.73m2 Hepatic impairment subject (in addition) * Subjects with severe ascites Healthy subject (in addition) * History or presence of any parenchymal hepatic disease * Positive test for hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCVAb)